Señales en vivo de DRUG | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases...

Stats
Volumen de hoy	6 013.00
Volumen promedio	24 788.00
Capitalización de mercado	4.75M
EPS	$0 ( 2024-02-06 )
Próxima fecha de ganancias	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.850
ATR14	$0.0150 (1.36%)

Bright Minds Biosciences Correlación

10 Correlaciones Más Positivas
IRBT	0.964
NDAQ	0.958
HCAQ	0.952
LGMK	0.934
INCR	0.93
REYN	0.929
ADTN	0.929
LSXMA	0.926
LSXMK	0.926
CFRX	0.924

10 Correlaciones Más Negativas
INSE	-0.959
MCFT	-0.956
PATK	-0.954
BCOR	-0.949
VAQC	-0.946
TZPSU	-0.941
LYTS	-0.94
ULTA	-0.937
TMKR	-0.936
AMTBB	-0.936

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bright Minds Biosciences Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-72 450.00 (0.00 %)
EPS:	$-1.980

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-72 450.00 (0.00 %)
EPS:	$-1.980

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$0

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-6 037.00 (0.00 %)
EPS:	$-6.15

Financial Reports:

No articles found.

Bright Minds Biosciences

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.